Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Cardiologists have raised this question after the disappointing results of the phase 3 OCEANIC-AF trial, in which the anti-XI peptide asundexian (Bayer) failed to demonstrate efficacy, leading to ...

Bayer AG BAYRY announced positive top-line ... The late-stage study, OCEANIC-AF, investigating asundexian compared with direct oral anticoagulant Eliquis (apixaban) in patients with atrial ...

Bayer AG (BAYRY) reports modest sales growth and debt reduction amid financial headwinds and strategic challenges.